nach oben

Clinical Drug Investigation

Erschienen in:

01.03.2002 | Review Article

Acarbose

An Update of Its Therapeutic Use in Diabetes Treatment

verfasst von: Prof. Dr Heiner Laube

Erschienen in: Clinical Drug Investigation | Ausgabe 3/2002

Einloggen, um Zugang zu erhalten

Abstract

Oral antidiabetic drugs are becoming increasingly important as rates of type 2 diabetes, uncontrolled by dietary intervention alone, increase around the world. Therapeutic agents that target the early stages of type 2 diabetes, such as the α-glucosidase enzyme inhibitor acarbose, which reduces postprandial hyperglycaemia and hyperinsulinaemia, now have a more prominent role to play in diabetes management in view of increasing evidence that the postprandial state is an important contributing factor to the development of atherosclerosis.

This review provides an update on the role of acarbose in present-day diabetes care. Acarbose is a first-line treatment for newly diagnosed patients with type 2 diabetes, those who have high postprandial blood glucose and for patients where dietary treatment alone provides inadequate glycaemic control. Acarbose lowers blood glucose when administered as monotherapy and in combination with other oral antidiabetic drugs. It reliably reduces levels of glycated haemoglobin (HbA_1c) and also increases insulin sensitivity; however, unlike insulin and the sulphonylureas, acarbose has not been associated with bodyweight gain.

The aim of this review is to present clinical data on the pharmacology and efficacy of acarbose in the treatment of patients with type 2 diabetes mellitus. It is not intended to present a comprehensive review of the treatment of diabetes mellitus in general.

¹Use of tradenames is for product identification only and does not imply endorsement.

Campbell IW: Type 2 diabetes mellitus: the silent killer. Pract Diab Int 2001; 18(6): 187–91CrossRef

DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86CrossRef

UK Prospective Diabetes Study Group, UK prospective diabetes study 16: overview of 6 years therapy of type 2 diabetes: a progressive disease. Diabetes 1995; 44: 1249–58CrossRef

Ohkubo Y, Kishikawa H, Araki E. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non insulin dependent diabetes mellitus: a randomized prospective 5-year study. Diabetes Res Clin Pract 1995; 28: 103–17PubMedCrossRef

Müller L. Microbial glycosidase inhibitors. Biotechnology 1985; 4(18): 2–37

Mertes G. Efficacy and safety of acarbose in the treatment of type 2 diabetes: data from a 2-year surveillance study. Diabetes Res Clin Pract 1998; 40: 63–70PubMedCrossRef

Mertes G: Safety and efficacy of acarbose in the treatment of type 2 diabetes. Data from a 5-year surveillance study. Diabetes Res Clin Pract 2001; 52: 193–204PubMedCrossRef

Hara T, Sakakibara F, Nakamura J, et al. An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM. Diabetes Care 1996; 19(6): 642–7PubMedCrossRef

Wolever TMS, Chiasson JL, Josse RG, et al. No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30–60% of energy from carbohydrate. Diabetes Care 1998; 21: 1612–8PubMedCrossRef

10.

Lindström J, Tuomilehto J, Spenglert M. Acarbose treatment does not change the habitual diet of patients with type 2 diabetes mellitus. Diabet Med 2000; 17: 20–5PubMedCrossRef

11.

Costa B, Pinol C. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure; a randomised multicentric trial in primary health care. Diabetes and Acarbose Research Group. Diabetes Res Clin Pract 1997; 38(1): 33–40PubMedCrossRef

12.

Fölsch UR, Schwamen EV, Graf S, et al. Influence of long-term intake of a glycoside hydrolyse inhibitor on pancreatic exocrine secretion and contents of intestinal brush-border enzymes. Gastroenterol Clin Biol 1979; 3: 286–7

13.

Lebowitz HE. α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Review 1998; 6(2): 132–45

14.

Caspary WF. Pathophysiology and clinical aspects of the malabsorption syndrome. In: Structure and function of the small intestine. Caspary WF, editor. Amsterdam: Excerpta Medica, 1987, 47

15.

May C. Efficacy and tolerability of stepwise dosage of acarbose in patients with non-insulin-dependent diabetes (NIDDM) treated with sulfonylureas. Diabetes u. Stoffwechsel 1995; 4: 3–7

16.

Müting D. Acarbose bei der Behandlung von Diabetikern mit gleichzeitiger Leberzirrhose. Therapiewoche 1984; 34: 2566–72

17.

Scheppach W, Fabian C, Ahrens F, et al. Effect of starch malabsorption on colonic function and metabolism in humans. Gastroenterology 1988; 95: 1549–55PubMed

18.

Morgan MY, Alonso M, Stanger LC. Lactitol and lactulose for the treatment of subclinical encephalopathy in cirrhotic patients. A randomised, cross-over study. J Hepatol 1989; 8: 208–17PubMedCrossRef

19.

Zillikens MC, Swart GR, Van den Berg JWO, et al. Effects of glucosidase inhibitor acarbose in patients with liver cirrhosis. Aliment Pharmacol Ther 1989; 3: 453–9PubMedCrossRef

20.

Holt H, Weiderpass E, Gridley G, et al. Diabetes mellitus and risk of large bowel cancer. J Natl Cancer Inst 1997; 89: 660–1CrossRef

21.

Bloomgarden ZT. The European Association for the Study of Diabetes. Annual Meeting, 1998. Diabetes Care 1999; 22:(7) 1209–15PubMed

22.

Ahr HJ, Boberg M, Krause HP, et al. Pharmacokinetics of acarbose. Arzneimittelforschung 1989; 39: 1254–60PubMed

23.

Salehi A, Panagiotidis G, Hakan Borg LA, et al. The pseudotetrasaccharide acarbose inhibits pancreatic islet glucan-1, 4-α-glucosidase activity in parallel with a suppressive action on glucose-induced insulin release. Diabetes 1995; 44: 830–6PubMedCrossRef

24.

Zhang TM, Malaisse WJ. Acarbose internalisation in pancreatic islet cells. Med Sci Res 1994; 22: 479–80

25.

Laube H, Aubell R, Schmitz H, et al. Acarbose an effective therapy in lowering postprandial hyperglycemia in obese patients with type-II diabetes mellitus. In: Creutzfeld W, editor. Proceedings of the First International Symposium on Acarbose; Excerpta Medica, Amsterdam, 1982: 344–7

26.

Toeller M: Modulation of intestinal glucose absorption: postponement of glucose absorption by alpha-glucosidase inhibitors. In: Mogensen CE, Standl E, editors. Pharmacology of Diabetes. Berlin: de Gruyter, 1991: 93–11227

27.

Hasche H, Mertes G, Bruns C, et al. Effects of acarbose treatment in type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study. Diabetes Nutr Metab 1999; 12: 277–85PubMed

28.

Baron A, Neumann C, PROTECT Study Group. PROTECT interim results: a large multicenter study of patients with type II diabetes. Clin Ther 1997; 19(2): 282–95PubMedCrossRef

29.

Coniff RF, Shapiro JA, Robbins D, et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. Diabetes Care 1995; 18: 817–24PubMedCrossRef

30.

Hanefeld M, Fischer S, Schulze J, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991; 14: 732–7PubMedCrossRef

31.

Tuomilehto J. Acarbose monotherapy in treatment of non-insulin-dependent diabetes mellitus. A review. In: Creutzfeldt W, editor. Proceedings of the Second International Symposium on Acarbose; 1987. Berlin Springer Verlag, Berlin, Heidelberg, New York, London, 1988: 105–16

32.

Goto Y, Toyoda T, Oikawa S, et al. Long term administration of BAY g 5421 (acarbose) in NIDDM. Yakuri to Chiro 1989; 17: 77–83

33.

Balfour JA, McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993; 46(6): 1025–54PubMedCrossRef

34.

Meneilly GS, Ryan EA, Radziuk J. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000; 23(8): 1162–7PubMedCrossRef

35.

Seifarth C, Bergmann Y, Nauck M, et al. Prolonged and enhanced secretion of glucagon like peptide-1 (7–36 amide) after oral sucrose due to alpha glucosidase inhibition (acarbose) in type 2 diabetic patients. Diabet Med 1998; 15: 485–91PubMedCrossRef

36.

Holman RR, Cull C, Turner R, et al. Acarbose improves control over three years in type 2 diabetes. Diabetes 1998; 47Suppl 1: A93

37.

Hoffmann J, Spengler M. The Essen I Study: efficacy of 24 week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients. Diabetes Care 1994; 17(6): 561–6PubMedCrossRef

38.

Salman S, Salman F, Satman I, et al. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. Curr Med Res Opin 2001; 16(4): 296–306PubMedCrossRef

39.

Uttenthal LO, Ukponmwan OO, Wood SM, et al. Long term effects of intestinal alpha-glucosidase inhibition on postprandial glucose, pancreatic and gut hormone response and fasting serum lipids in diabetics on sulfonylureas. Diabet Med 1986; 3: 155–60PubMedCrossRef

40.

Hillebrand I, Boehme K, Frank G, et al. The effects of alpha-glucosidase inhibitor BAY g 5421 (acarbose) on meal stimulated elevations of circulating glucose, insulin and triglyceride level in man. Res Exp Med (Berl) 1979; 175: 81–6CrossRef

41.

Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 1994; 121(12): 928–35PubMed

42.

Reaven GM, Lardinois CK, Greenfield MS, et al. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care 1990; 13Suppl 3: 32–6PubMed

43.

Wolever Th, Singer W, Chiasson JL, et al. Acarbose improves abnormal insulin metabolism in type 2 diabetics. Clin Res 1993; 41(2): 360 A

44.

Lindstrom J, Tuomilehto J, Spengler M: The effect of acarbose on dietary nutrient intake and metabolic control in NIDDM patients. Diabetologia 1996; 39Suppl 1: 739

45.

Sachse G, Mäser E, Laube H, et al. Diabetische Stoffwechsellage unter langffristiger Acarbosetherapie. Therapiewoche 1982; 32: 3587–90

46.

William-Olsson T, Krotkiewski M, Sjöström L: Relapse-reducing effects of acarbose after weight reduction in severely obese subjects. Journal of Obesity and Weight Regulation 1985; 4: 20–32

47.

Braun D, Schönherr U, Mitzkat HJ. Efficacy of acarbose monotherapy in patients with type 2 diabetes: a double-blind study conducted in general practice. Endocrinology and Metabolism 1996; 3: 275–80

48.

Gutzwiller JR Glucagon like peptide-1 is a physiologic regulator of food intake in humans. Gastroenterology 1997; 112: A1153

49.

Haffner SM, Flücker K, Hanefeld M, et al. Glibenclamide, but not acarbose, increases leptin concentrations parallel to changes in insulin in subjects with NIDDM. Diabetes Care 1997; 20(9): 1430–4PubMedCrossRef

50.

Shinozaki K, Suzuki M, Ikebuchi M, et al. Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor in non-diabetic hyperinsulinemic subjects. Metabolism 1996; 45: 731–7PubMedCrossRef

51.

Chiasson JL, Josse RG, Leiter LA, et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996; 19: 1190–3PubMedCrossRef

52.

Laube H, Linn Th, Heyen P. The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Exp Clin Endocrinol Diabetes 1998; 106: 231–33PubMedCrossRef

53.

Calle-Pascual A, Garcia-Honduvilla J, Martin-Alvarez PJ, et al. Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo. Diabetes Metab 1996; 22: 201–2PubMed

54.

Jenney A, Proietto J, O’Dea K, et al. Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity. Diabetes Care 1993; 16: 499–502PubMedCrossRef

55.

Schnack C, Prager RJF, Winkler J, et al. Effect of 8 week alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output and peripheral insulin sensitivity in poorly controlled type 2 diabetic patients. Diabetes Care 1989; 12: 537–43PubMedCrossRef

56.

Holman RR, Turner RC, Cull CA, et al. A randomised double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 1999; 22(6): 960–4PubMedCrossRef

57.

Qualmann C, Nauck MA, Holst JJ, et al. Glucagon-like peptide 1 (GLP-1) (17–36 amide) secretion in response to luminal sucrose from the upper and lower gut: a study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995; 30: 892–6PubMedCrossRef

58.

Nauck MA, Holst JJ, Willms B, et al. Glucagon-like-peptide 1 (GLP-1) as a new therapeutic approach for type 2 diabetes. Exp Clin Endocrinol Diabetes 1997; 105: 187–95PubMedCrossRef

59.

Göke B, Herrmann C, Göke R, et al. Intestinal effects of alpha-glucosidase inhibitors: absorption of nutrients and enterohormonal changes. Eur J Clin Invest 1994; 24Suppl 3: 25–30PubMed

60.

Requejo F, Uttenthal LO, Bloom SR. Effect of alpha-glucosidase inhibition and viscous fibre on diabetic control and postprandial gut hormone responses. Diabet Med 1990; 7: 515–20PubMedCrossRef

61.

Nestel PJ, Bazelmans J, Reardon MF, et al. Lower triglyceride production during carbohydrate-rich diets trough acarbose, a glucoside hydrolase inhibitor. Diabete Metab 1985; 11: 316–7PubMed

62.

Clissold SP, Edwards C. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1988; 35: 214–43PubMedCrossRef

63.

Zavaroni I, Reaven GM. Inhibition of carbohydrate-induced hypertriglyceridemia by a disaccharidase inhibitor. Metabolism 1981; 30: 417–20PubMedCrossRef

64.

Malaguarnera M, Giugno I, Ruello P, et al. Acarbose is an effective adjunct to dietary therapy in the treatment of hypertriglyceridaemias. Br J Clin Pharmacol 1999; 48: 605–9PubMedCrossRef

65.

Malaguarnera M, Giugno I, Panebianco MP, et al. Beneficial effects of acarbose on familiar hypertriglyceridemias. Int J Clin Pharmacol Ther 1998; 36(8): 441–5PubMed

66.

Maruhama Y, Sasaki M, Ninomiya K, et al. The efficacy of acarbose on hyperinsulinemia and hyperlipidemia in overweight patients. Clinical Report 1995; 29(3): 172–80

67.

Baron AD, Eckel RH, Schmeiser L, et al. The effect of short term alpha glucosidase inhibition on carbohydrate and lipid metabolism in type-2-diabetics. Metabolism 1987; 36: 409–15PubMedCrossRef

68.

Kado S, Murakami T, Aoki A, et al. Effect of acarbose on postprandial metabolism in type 2 diabetes mellitus. Diab Res Clin Pract 1998; 41: 49–55CrossRef

69.

Homma Y, Irie N, Yano Y, et al. Changes in plasma lipoprotein levels during medication with a glucoside-hydrolase inhibitor (acarbose). Tokai J Exp Clin Med 1982; 7: 393–6PubMed

70.

Maruhama Y, Nagasaki A, Kanazawa Y, et al. Effects of glucoside hydrolase inhibitor (Bay g 5421) on serum lipids, lipoproteins and bile acids, faecal fat and bacterial flora, and intestinal gas production in hyperlipidemic patients. Tohoku J Exp Med 1980; 132: 453–62PubMedCrossRef

71.

Shimoyama T, Hori S, Tamura K, et al. Effects of acarbose on faecal microflora of hyperlipidemic patients. In: Creutzfelddt W, editor. Proceedings of the First International Symposium on Acarbose; Oct 1981, Montreux Excerpta Medica, Amsterdamn 1982: 461–70

72.

Leonhardt W, Hanefeld M, Fischer S, et al. Beneficial effects on serum lipids in noninsulin-dependent diabetics by acarbose treatment. Arzneimittelforschung 1991; 41: 735–8PubMed

73.

Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin or placebo in dietary-treated NIDDM patients: The Essen-II Study. Am J Med 1997; 103: 483–90PubMedCrossRef

74.

Couet C, Ulmer M, Hamdaoui M, et al. Metabolic effects of acarbose in young healthy men. Eur J Clin Nutr 1989; 43: 187–96PubMed

75.

Tulp OL, Abdollahi A, Stevens C, et al. The effects of the intestinal glucosidase inhibitor acarbose on cholesterologenesis in corpulent rats. Comp Biochem Physiol A 1991; 100(3): 763–8PubMedCrossRef

76.

Rosenthal J, Mauersberger H. Hypertension in type 2 diabetic patients -effects of endogenous insulin and antidiabetic therapies. Am J Hypertens 2000; 13: 81ACrossRef

77.

Ceriello A, Taboga C, Tonutti L, et al. Post meal coagulation in diabetes mellitus: the effect of acarbose. Diabetologia 1996; 39: 469–73PubMedCrossRef

78.

Ridker PM, Hennekens CH, Cerskus A, et al. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90: 2236–40PubMedCrossRef

79.

The Cochrane Controlled Trial Register. In: The Cochrane Library, Issue 1, 2001; Oxford. Update Software, Updated quarterly [online]. Available from URL: http://www.update-software.com(zuletztwww.update-software.com [Accessed 2001 Mar 21]

80.

Santeusanio F, Ventura MM, Contadinbi S, et al. Efficacy and safety of two different dosages of acarbose in non-insulin dependent diabetic patients treated by diet alone. Diabetes Nutr Metab 1993; 6: 147–54

81.

Fischer S, Hanefeld M, Spengler M, et al. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Acta Diabetol 1998; 35: 34–40PubMedCrossRef

82.

Hollander PA. Safety profile of acarbose, an alpha glucosidase inhibitor. Drugs 1993; 44Suppl 2: 47–53

83.

Harrower ADB, Harrower A, Jack H. Effect of fiber intake and meal pattern on gastrointestinal symptoms with acarbose. Diabetes Care 1999; 22(7): 1227PubMedCrossRef

84.

Spengler M, Hobler H, Cagatay M. Long-term tolerability of acarbose. In: Lefèbvre PJ, Standl E, editors. New aspects in diabetes. Treatment strategies with alpha-glucosidase inhibitors. De Gruyter, Berlin: 1992: 286–88

85.

Rosak CH, Haupt E, Walter TH, et al. Alteration of insulin secretion and blood glucose course under glibenclamide by acarbose in type 2 diabetic patients: additive blood glucoselowering effect and reduced risk for hypoglycemia. Diabetes 2000; 49(Suppl 1): A348

86.

Gentile S, Turco S, Guarino G, et al. Aminotransferase activity and acarbose treatment in patients with type-2 diabetes. Diabetes Care 1999; 22(7): 1217PubMedCrossRef

87.

Ben-Am H, Krivo N, Nagachandran P, et al. An interaction between digoxin and acarbose. Diabetes Care 1999; 22(5): 860–1CrossRef

88.

Gérard J, Lefèbvre PJ, Luyckx AS. Glibenclamide pharmacokinetics in acarbose-treated type 2 diabetics. Eur J Clin Pharmacol 1984; 27: 233–6PubMedCrossRef

89.

Hillebrand I, Graefe KH, Bischoff H, et al. Serum digoxin and propanolol levels during acarbose treatment. Diabetologia 1981; 21: 282

90.

Halimi S, Le Berre MA, Grangè V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with type 2 diabetes inadequately controlled with metformin: a double-blind placebo-controlled study. Diabetes Res Clin Pract 2000; 50: 49–56PubMedCrossRef

91.

Coniff RF, Shapiro JA, Seaton TB. Long term efficacy of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med 1994; 154(21): 2442–8PubMedCrossRef

92.

Coniff RF, Shapiro TB, Hoogwerf BJ, et al. A double blind placebo controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin requiring type 2 diabetes. Diabetes Care 1995; 18: 928–32PubMedCrossRef

93.

Kovacevic I, Profozic V, Skrabalo Z, et al. Multicentric clinical trial to assess efficacy and tolerability of acarbose in comparison to glibenclamide and placebo. Diabetologia Croatica 1997; 26(2): 83–9

94.

Hotta N, Kakuta H, Sano T, et al. Long term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus. A placebo-controlled double-blind study. Diabet Med 1993; 10: 134–8PubMedCrossRef

95.

Kelley DE, Schimel D, Bidot P, et al. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care 1998; 21(12): 2056–61PubMedCrossRef

96.

Rosenstock J, Nadean D, Brown A, et al. Efficacy and safety of acarbose in metformin treated patients with Type 2 Diabetes. Diabetes Care 1998; 21: 2050–5PubMedCrossRef

97.

Willms B, Ruge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulfonylureas: a randomised, placebo-controlled study. Diabet Med 1999; 16: 755–61PubMedCrossRef

98.

Rybka J, Gregorová A, Zymdlena A, et al. Klinische Studie mit Acarbose. Drug Invest 1990; 2(4): 264–7CrossRef

99.

Pinol C, Guardiola E, Soler J, et al. A double blind, randomised, placebo controlled study to assess the maximum insulin dose reduction achieved with acarbose in the treatment of insulin-requiring type 2 diabetic patients. Diabetes Nutr Metab 1998; 11: 242–8

100.

Güvener N, Gedik O. Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients. Acta Diabetol 1999; 36: 93–7PubMedCrossRef

101.

Juntti-Berggren L, Pigon J, Holst JJ, et al. Influence of acarbose on postprandial insulin requirements in patients with type 1 diabetes. Diabetes Nutr Metab 2000; 13: 7–12PubMed

102.

Dimitriadis G, Karaiskos C, Raptis S. Effects of prolonged (6 months) alpha glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin dependent diabetes mellitus. Horm Metab Res 1986; 18: 253–5PubMedCrossRef

103.

Tattersal R. Alpha glucosidase inhibition as an adjunct to the treatment of type 1 diabetes. Diabet Med 1993; 10: 688–93CrossRef

104.

Hollander P, Pi-Sunyer X, Coniff RF. Acarbose in the treatment of type 1 diabetes. Diabetes Care 1997; 20(3): 248–53PubMedCrossRef

105.

Sailer D, Gossner L, Schönfuss I. Einfluss von Acarbose auf den Spritz-Eßabstand beim Typ1 Diabetes. Fortschr Med 1992; 110: 479–80PubMed

Titel: Acarbose
An Update of Its Therapeutic Use in Diabetes Treatment
verfasst von: Prof. Dr Heiner Laube
Publikationsdatum: 01.03.2002
Verlag: Springer International Publishing
Erschienen in: Clinical Drug Investigation / Ausgabe 3/2002
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI: https://doi.org/10.2165/00044011-200222030-00001

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2002

Pharmacokinetics of the Effect of Nebivolol 5mg on Airway Patency in Patients with Mild to Moderate Bronchial Asthma and Arterial Hypertension

Cohort Experience in 39 Psychiatric Outpatients with High Doses of an Enteric-Coated Weekly Formulation of Fluoxetine

Non-Animal Stabilised Hyaluronic Acid in the Treatment of Osteoarthritis of the Knee

Role of Ademetionine (S-Adenosylmethionine) in Cyclosporin-Induced Cholestasis

Ciclopiroxolamine Cream 1% in the Treatment of Seborrhoeic Dermatitis

Stevens-Johnson Syndrome Associated with Codeine in a Child